Zoetis Inc. $ZTS Shares Sold by Community Trust & Investment Co.

Community Trust & Investment Co. trimmed its position in Zoetis Inc. (NYSE:ZTS) by 73.3% in the second quarter, Holdings Channel.com reports. The fund owned 30,914 shares of the company’s stock after selling 85,005 shares during the period. Community Trust & Investment Co.’s holdings in Zoetis were worth $2,221,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. J. Stern & Co. LLP boosted its holdings in Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares during the period. Norges Bank acquired a new stake in shares of Zoetis during the fourth quarter worth $734,425,000. Vanguard Group Inc. raised its holdings in shares of Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares during the period. Ruane Cunniff & Goldfarb L.P. bought a new position in shares of Zoetis in the 1st quarter worth about $286,660,000. Finally, Van ECK Associates Corp lifted its position in shares of Zoetis by 269.0% in the 4th quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock worth $300,340,000 after buying an additional 1,740,113 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ZTS shares. Barclays lowered their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Stifel Nicolaus decreased their target price on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research note on Friday, June 26th. JPMorgan Chase & Co. lowered their target price on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Friday. TD Cowen dropped their price target on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. Finally, HSBC cut their price target on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average price target of $115.50.

Zoetis Trading Down 6.1%

Shares of NYSE:ZTS opened at $72.53 on Friday. The company has a market cap of $30.41 billion, a PE ratio of 11.95, a P/E/G ratio of 1.34 and a beta of 0.74. The company’s 50-day moving average price is $76.66 and its 200 day moving average price is $100.75. Zoetis Inc. has a fifty-two week low of $71.47 and a fifty-two week high of $160.48. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 70.95%. The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the prior year, the firm earned $1.76 EPS. Zoetis’s quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.2 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is 35.16%.

Insider Activity at Zoetis

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction on Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 11,650 shares of company stock worth $886,384 in the last three months. 0.22% of the stock is owned by company insiders.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.